115 related articles for article (PubMed ID: 31238062)
21. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
22. Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation.
Tomita Y; Uehara S; Takiguchi S; Nakamura M
Transplant Proc; 2023 May; 55(4):792-796. PubMed ID: 37100735
[TBL] [Abstract][Full Text] [Related]
23. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
Niemczyk M; Zegarska J; Pawłowska M; Wyzgał J; Ciszek M; Paczek L
Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
[TBL] [Abstract][Full Text] [Related]
24. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation.
Klaasen RA; Bergan S; Bremer S; Daleq L; Andersen AM; Midtvedt K; Skauby MH; Vethe NT
Ther Drug Monit; 2018 Oct; 40(5):558-566. PubMed ID: 30086087
[TBL] [Abstract][Full Text] [Related]
26. Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation.
Tomei P; Masola V; Granata S; Bellin G; Carratù P; Ficial M; Ventura VA; Onisto M; Resta O; Gambaro G; Chilosi M; Lupo A; Zaza G
J Nephrol; 2016 Dec; 29(6):881-891. PubMed ID: 27026415
[TBL] [Abstract][Full Text] [Related]
27. Association Between the Intracellular Tacrolimus Concentration in CD3 + T Lymphocytes and CD14 + Monocytes and Acute Kidney Transplant Rejection.
Udomkarnjananun S; Francke MI; Dieterich M; van de Velde D; Verhoeven JGHP; Boer K; Clahsen-Van Groningen MC; De Winter BCM; Baan CC; Hesselink DA
Ther Drug Monit; 2022 Oct; 44(5):625-632. PubMed ID: 35358111
[TBL] [Abstract][Full Text] [Related]
28. A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation.
Rascio F; Pontrelli P; Accetturo M; Oranger A; Gigante M; Castellano G; Gigante M; Zito A; Zaza G; Lupo A; Ranieri E; Stallone G; Gesualdo L; Grandaliano G
J Pathol; 2015 Sep; 237(1):72-84. PubMed ID: 25925804
[TBL] [Abstract][Full Text] [Related]
29. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
30. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
Saliba F; Fischer L; de Simone P; Bernhardt P; Bader G; Fung J
Ann Transplant; 2018 Oct; 23():751-757. PubMed ID: 30361470
[TBL] [Abstract][Full Text] [Related]
31. Increased sensitivities of peripheral blood mononuclear cells to immunosuppressive drugs in cirrhosis patients awaiting liver transplantation.
Mijiti A; Matsuno N; Iwahori T; Takeuchi H; Nagao T; Oka K; Hirano T
Cell Transplant; 2006; 15(10):885-91. PubMed ID: 17299993
[TBL] [Abstract][Full Text] [Related]
32. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
[TBL] [Abstract][Full Text] [Related]
33. Effect of immunosuppressive drugs on DNA repair in human peripheral blood mononuclear cells.
Herman-Edelstein M; Rozen-Zvi B; Zingerman B; Lichtenberg S; Malachi T; Gafter U; Ori Y
Biomed Pharmacother; 2012 Mar; 66(2):111-5. PubMed ID: 22244961
[TBL] [Abstract][Full Text] [Related]
34. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
van Rossum HH; Romijn FP; Smit NP; de Fijter JW; van Pelt J
Biochem Pharmacol; 2009 Apr; 77(7):1206-12. PubMed ID: 19154728
[TBL] [Abstract][Full Text] [Related]
35. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus.
Demmers MW; Baan CC; Janssen M; Litjens NH; Ijzermans JN; Betjes MG; Weimar W; Rowshani AT
Transplantation; 2014 Jan; 97(1):47-55. PubMed ID: 24157471
[TBL] [Abstract][Full Text] [Related]
36. Potential cardiovascular risk factors in paediatric renal transplant recipients.
Ferraris JR; Ghezzi L; Waisman G; Krmar RT
Pediatr Nephrol; 2006 Jan; 21(1):119-25. PubMed ID: 16252106
[TBL] [Abstract][Full Text] [Related]
37. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
38. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
39. Karyopherins: potential biological elements involved in the delayed graft function in renal transplant recipients.
Zaza G; Rascio F; Pontrelli P; Granata S; Stifanelli P; Accetturo M; Ancona N; Gesualdo L; Lupo A; Grandaliano G
BMC Med Genomics; 2014 Mar; 7():14. PubMed ID: 24625024
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
Kagaya H; Niioka T; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
